AcquisitionsJul 6, 2026, 04:12 PM
Incyte Completes $1.25B Acquisition of Vega Therapeutics
AI Summary
Incyte Corporation announced the completion of its previously disclosed acquisition of Vega Therapeutics, Inc., a subsidiary of Star Therapeutics LLC. This acquisition significantly expands Incyte's hematology portfolio by adding VGA039, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease (VWD). Incyte paid $1.25 billion upfront, with Star Therapeutics eligible for up to an additional $750 million in sales milestones, and expects to record the transaction as a one-time R&D expense in the third quarter and full year 2026.
Key Highlights
- Incyte completed the acquisition of Vega Therapeutics, Inc.
- The acquisition adds VGA039, a novel monoclonal antibody for von Willebrand disease (VWD).
- VGA039 is in Phase 3 development and strengthens Incyte's hematology portfolio.
- Incyte paid $1.25 billion upfront for Vega Therapeutics.
- Star Therapeutics is eligible for up to $750 million in sales milestone payments.
- VGA039 has received FDA Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations.
- The transaction is expected to be a one-time R&D expense in Q3 and full year 2026.
Price Impact
More from INCY